Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, 4700 Sunset Bl, Los Angeles, CA, USA.
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Int Urol Nephrol. 2018 May;50(5):963-971. doi: 10.1007/s11255-018-1837-6. Epub 2018 Mar 12.
The early period after chronic kidney disease (CKD) patients transition to end-stage renal disease (ESRD) represents the highest mortality risk but is variable among different patient populations and clinical circumstances. We compared early mortality outcomes among a diverse CKD population that transitioned to ESRD.
A retrospective cohort study (1/1/2002 through 12/31/2013) of CKD patients (age ≥ 18 years) who transitioned to peritoneal dialysis (PD), hemodialysis (HD) with arteriovenous fistula/grafts, and HD with catheters was performed. Multivariable Cox regression modeling was used to estimate 6-month all-cause mortality hazard ratios (HR) among the three treatment groups after adjustment for patient and clinical characteristics.
Among 5373 ESRD patients (62.7 years, 41.3% females, 37.5% Hispanics, 13.3% PD, 34.9% HD with fistula/graft, 51.8% HD with catheter), 551 (10.3%) died at 6 months. Mortality rates were highest immediately after transition (299 deaths per 1000 person-years in first month). Compared to PD patients, the 6-month mortality HR (95% CI) was 1.87 (1.06-3.30) in HD with fistula/graft patients and 3.77 (2.17-6.57) in HD with catheter patients. Inpatient transition (HR 1.32), acute kidney injury (HR 2.06), and an eGFR ≥ 15 vs 5-9 (HR 1.68) at transition were also associated with higher early mortality risk.
Among a diverse CKD population who transitioned to ESRD, we observed considerable differences in early mortality risk among PD, HD with fistula/graft, and HD with catheter patients. The identification of patient-specific and clinical environmental factors related to high early mortality may provide insights for managing advanced stages of CKD and shared decision making.
慢性肾脏病(CKD)患者过渡到终末期肾病(ESRD)后的早期阶段代表着最高的死亡风险,但在不同的患者人群和临床情况下存在差异。我们比较了过渡到 ESRD 的不同 CKD 人群的早期死亡结局。
这是一项回顾性队列研究(2002 年 1 月 1 日至 2013 年 12 月 31 日),纳入了 CKD 患者(年龄≥18 岁),这些患者过渡到腹膜透析(PD)、带动静脉瘘/移植物的血液透析(HD)和带导管的血液透析。使用多变量 Cox 回归模型,在调整患者和临床特征后,估计三组治疗患者在 6 个月时全因死亡的风险比(HR)。
在 5373 名 ESRD 患者(62.7 岁,41.3%为女性,37.5%为西班牙裔,13.3%为 PD,34.9%为带瘘/移植物的 HD,51.8%为带导管的 HD)中,有 551 人(10.3%)在 6 个月时死亡。死亡率在过渡后立即最高(第一个月每 1000 人中有 299 人死亡)。与 PD 患者相比,带瘘/移植物的 HD 患者和带导管的 HD 患者在 6 个月时的死亡率 HR(95%CI)分别为 1.87(1.06-3.30)和 3.77(2.17-6.57)。住院过渡(HR 1.32)、急性肾损伤(HR 2.06)以及 eGFR≥15 与 5-9(HR 1.68)相比,也是早期死亡风险较高的相关因素。
在过渡到 ESRD 的不同 CKD 人群中,我们观察到 PD、带瘘/移植物的 HD 和带导管的 HD 患者之间的早期死亡率风险存在显著差异。确定与高早期死亡率相关的患者特定和临床环境因素,可能为管理 CKD 的晚期阶段和共同决策提供见解。